{
  "outcomes_metadata": {
    "timestamp": "2025-10-02T13:59:04.877697",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 143,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "long-term survival",
        "improved survival",
        "survival (long-term)",
        "perioperative mortality",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST criteria)",
        "progression-free survivorship",
        "death",
        "mortality"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "tumor response rate",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "response rates (multiphase computed tomography with contrast)",
        "response rates (magnetic resonance imaging with contrast)",
        "partial response (PR)",
        "complete response (CR)",
        "complete remission",
        "minor response (reduction of tumour size by 25 to 50%)",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "tumor reduction",
        "local tumour control",
        "success rate (downstaging/bridging)",
        "local control",
        "imaging response (RECIST criteria)",
        "imaging response (mRECIST criteria)",
        "mRECIST response"
      ],
      "progression_measures": [
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time-to-progression",
        "time to radiological disease progression",
        "progression",
        "disease progression",
        "reassessment in progression classification",
        "bridging therapy (reduction of progression)",
        "progression-free state",
        "progressive illness state",
        "tumour spread (size, number, vascular invasion, extrahepatic spread; TNM system)",
        "recurrence",
        "disease recurrence",
        "delay of recurrence",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "disease control",
        "benefit from molecular chemoembolization",
        "benefit from radioembolization",
        "benefit from combination of loco-regional methods (chemoembolization plus thermoablation)",
        "benefit from transplantation",
        "benefit from resection",
        "benefit from thermoablation",
        "benefit from radiofrequency ablation",
        "benefit from microwave thermoablation",
        "effectiveness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (ultrasonography not appropriate)",
        "completeness of ablation procedure (multiphase computed tomography with contrast)",
        "down-staging"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse reactions (general)",
        "treatment-emergent adverse events (TEAEs)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (Grade ≥ 3)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "complication incidence",
        "complications",
        "post-treatment complications",
        "intraoperative complications",
        "undesirable effects",
        "side-effects (biopsy)",
        "long-term treatment-related complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity",
        "grade 3 adverse events",
        "grade 3 adverse reactions",
        "grade 4 adverse reactions",
        "secondary cancer",
        "serious adverse events",
        "bleeding",
        "haemorrhagic events",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "haemorrhage",
        "rebleeding",
        "portal vein thrombosis",
        "liver failure",
        "hepatic encephalopathy",
        "hepatic insufficiency",
        "liver disorders",
        "liver-related morbidity",
        "jaundice (EORTC QLQ-HCC18)",
        "jaundice",
        "hypertension",
        "arterial thromboembolic events",
        "cerebral vascular accident",
        "cardiovascular arrest",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "sudden death",
        "renal events",
        "renal failure",
        "proteinuria",
        "hypothyroidism",
        "hyperthyroidism",
        "diabetes mellitus",
        "infusion reactions",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand-foot syndrome",
        "hand feeding reactions",
        "skin rash",
        "rash",
        "desquamation",
        "skin desquamation",
        "dry skin",
        "erythema",
        "pruritus",
        "dermatitis exfoliative",
        "acne",
        "hyperkeratosis",
        "folliculitis",
        "alopecia",
        "weight loss",
        "decreased weight",
        "decreased appetite",
        "anorexia",
        "fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "asthenia",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "back pain",
        "limb pain",
        "headache",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "influenza like illness",
        "nausea",
        "vomiting",
        "constipation",
        "diarrhoea",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro oesophageal reflux disease",
        "intestinal failure",
        "dysgeusia",
        "tinnitus",
        "cough",
        "dyspnoea",
        "pleural effusion",
        "respiratory failure",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hypophosphataemia",
        "increased ALT activity",
        "increased amylase",
        "increased lipase",
        "transient increase in transaminases",
        "creatinine increase",
        "leukopenia",
        "lymphopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "neurotoxicity",
        "peripheral sensory neuropathy",
        "dysphonia",
        "nutrition",
        "body image",
        "depression",
        "distress",
        "physical complaints",
        "psychosocial complaints",
        "emotional complaints",
        "social complaints",
        "spiritual complaints",
        "hypody",
        "hypersensitivity to monitoring",
        "folliculitis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "erythema",
        "flushing",
        "rhinorrhoea",
        "erectile dysfunction",
        "death"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "treatment-related deaths",
        "treatment-related mortality",
        "secondary cancer",
        "brain haemorrhage",
        "cerebral vascular accident",
        "cardiovascular arrest",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "sudden death",
        "sepsis"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-5L",
        "EQ-5D-3L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "health status (EQ-5D visual analogue scale)",
        "health-related quality of life (HRQoL)",
        "FACT-G (Functional Assessment of Cancer Therapy – General)",
        "FACT-Hep",
        "FHSI-8 questionnaire",
        "SF-36",
        "visual analogue scale",
        "overall quality of life (measured with a validated and reliable instrument)",
        "quality of life weights",
        "health state utility values"
      ],
      "functional_status": [
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "overall condition (ECOG Performance Status)",
        "Barcelona Clinic Liver Cancer (BCLC) staging system",
        "prognosis (BCLC staging system)",
        "prognosis (Child-Pugh score)",
        "liver function (Child-Pugh scale)",
        "prognosis (MELD score)"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "nutrition",
        "body image",
        "distress",
        "physical complaints",
        "psychosocial complaints",
        "emotional complaints",
        "social complaints",
        "spiritual complaints",
        "time to deterioration",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 functional role subscale)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30 fitness subscale)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness analysis",
        "cost-benefit analysis",
        "cost per quality-adjusted life year (QALY)",
        "number needed to treat (NNT)",
        "number needed to harm (NNH)"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "resource utilization"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "time to clinically meaningful deterioration (EORTC QLQ-C30)",
        "time to clinically meaningful deterioration (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening (EQ-5D)",
        "time to symptom progression",
        "delay of recurrence",
        "down-staging",
        "success rate (downstaging/bridging)",
        "intention-to-treat analysis",
        "false positives",
        "tolerance of treatment",
        "early diagnosis",
        "risk of developing hepatocellular carcinoma",
        "risk indicator (alpha-fetoprotein)",
        "donor morbidity",
        "diagnosis (multiphasic CT and MRI, LI-RADS v2018)",
        "diagnosis (immunohistochemistry markers)",
        "diagnosis (panels of immunohistochemistry markers)",
        "diagnosis (genetic tests for metabolic diseases)",
        "diagnosis (paired tumour and non-tumour liver biopsy)",
        "diagnosis (non-invasive imaging-based criteria on CT, MRI, or CEUS)",
        "diagnosis (specialised molecular and genetic tests)",
        "diagnosis (pathological examination)",
        "diagnosis (differential diagnosis between HCC and other liver tumours)",
        "diagnosis (differential diagnosis between HCC and benign nodules)",
        "Social Code Standardized incidence rate"
      ],
      "biomarkers": [
        "plasma pharmacokinetics parameters",
        "pharmacokinetic/pharmacodynamic relationship",
        "pharmacokinetic parameters",
        "vital signs",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "risk indicator (alpha-fetoprotein)"
      ]
    }
  }
}